Acadia Pharmaceutica (ACAD)
$52.32 0.00 (0.00%)
19:12 EDT ACAD Stock Quote Delayed 30 Minutes
Previous Close $52.32
Market Cap 6.53B
PE Ratio -25.15
Volume (Avg. Vol.)
Day's Range 52.32 - 52.32
52-Week Range 21.56 - 58.72
Dividend & Yield N/A (N/A)
ACAD Stock Predictions, Articles, and Acadia Pharmaceutica News
- From InvestorPlace
- From the Web
Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.
Boeing, Aurora Cannabis, Pinterest, Corning and Acadia Pharmaceuticals were our top stock trades on Wednesday. See the charts now.
The biotechnology and pharmaceutical sectors continue to offer great value for investors, and these five Big Pharma stocks stand out from the crowd.
ACADIA Pharmaceuticals(ACAD) stock was falling hard today on a report with concerns about its Parkinson's drug Nuplazid.
These five biotech stocks are being hit particularly hard right now. Here's what investors should know about each of these stocks to sell.
Biotech's luck is changing as the trend looks to be upward and outward for the biotech stocks. These are the five to watch.
Earnings season is far from over. In addition to crucial economic indicators, there are a few earnings reports to keep an eye on next week.
2017 is likely to see quite a few mergers & acquisitions, and companies like BKS, NFLX and ACAD are all ripe for the M&A picking.
Acadia stock took a big leap on rumors that Pfizer (PFE) is interested in a buyout. But ACAD stock investors shouldn't get too excited yet.
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
The following stocks were moving the Manufacturing sector today.
Could we see a President Hillary Clinton? According to most polls, that's the likeliest outcome for Nov. 8. Get your portfolio prepared with the 16 best stocks to buy ahead of another White House stint for the Clintons.
Q4 is usually a winner for biotech stocks, but these stocks could deliver more than their fair share of wins during the coming three months.
Navellier RatingsPowered by Portfolio Grader